Cost-effectiveness analysis of iStent trabecular micro-bypass stent for patients with open-angle glaucoma in Colombia

References

• Beidoe G, Mousa SA. Current primary open-angle glaucoma treatments and future directions. Clin Ophthalmol 2012;6:1699-707
   PubMedGoogle Scholar
• Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology 2014;121:2081-90
   PubMed Web of Science ®Google Scholar
• Cedrone C, Mancino R, Cerulli A, et al. Epidemiology of primary glaucoma: prevalence, incidence, and blinding effects. Prog Brain Res 2008;173:3-14
   PubMed Web of Science ®Google Scholar
• Viaña JM, Pongo L, Castro H, et al. Incidencia del glaucoma en la región Grau. Rev peruana Oftalmol 1995;19:23-5
   Google Scholar
• Arieta CE, de Oliveira DF, Lupinacci AP, et al. Cataract remains an important cause of blindness in Campinas, Brazil. Ophthal Epidemiol 2009;16:58-63
   PubMed Web of Science ®Google Scholar
• Salomao SR, Cinoto RW, Berezovsky A, et al. Prevalence and causes of vision impairment and blindness in older adults in Brazil: the Sao Paulo Eye Study. Ophthal Epidemiol 2008;15:167-75
   PubMed Web of Science ®Google Scholar
• Cass H, Landers J, Benitez P. Causes of blindness among hospital outpatients in Ecuador. Clin Exp Ophthalmol 2006;34:146-51
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud y Protección Social, Organización Panamericana de la Salud. Análisis de situación de situación de salud visual en Colombia. Bogotá, DC: Ministerio de Salud y Protección Social; 2016.
   Google Scholar
• Jonas JB, Aung T, Bourne RR, et al. Glaucoma. Lancet 2017;390:2183-93
   PubMed Web of Science ®Google Scholar
• Ministerio de Salud y Protección Social. Resolución 5269 de 2017, by which the Health Benefits Plan is updated with charge to the Capitation Payment Unit (UPC, by its acronym in Spanish) (22 Dec 2017). Available at: www.minsalud.gov.co
   Google Scholar
• Saheb H, Ahmed IIK. Micro-invasive glaucoma surgery: current perspectives and future directions. Curr Opin Ophthalmol 2012;23:96-104
   PubMed Web of Science ®Google Scholar
• Prum Jr BE, Lim MC, Mansberger SL, et al. Primary open-angle glaucoma suspect preferred practice pattern® guidelines. Ophthalmology 2016;123:112–51
   PubMed Web of Science ®Google Scholar
• Henderer JD, Rapuano CJ. Ocular pharmacology. In: Brunton LL, Chabner BA, Knollmann BC, editors. Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 12^th edn. New York, NY: McGraw-Hill Education; 2011, 1787
   Google Scholar
• Docherty JR. Subtypes of functional aplha1-adrenoceptor. Cell Mol Life Sci 2010;67:405-17
   PubMed Web of Science ®Google Scholar
• Becker B. The effects of the carbonic anhydrase inhibitor, acetazoleamide, on the composition of the aqueous humor. Am J Ophthalmol 1955;40:129-36
   PubMed Web of Science ®Google Scholar
• Epstein DL, Grant WM. Carbonic anhydrase inhibitor side effects. Serum chemical analysis. Arch Ophthalmol 1977;95:1378-82
   PubMed Web of Science ®Google Scholar
• Zimmerman TJ. Pilocarpine. Ophthalmology 1981;88:85-8
   PubMed Web of Science ®Google Scholar
• Rolim de Moura C, Paranhos A Jr, Wormald R. Laser trabeculoplasty for open angle glaucoma. Cochrane Database Syst Rev 2007;(4):CD003919[TQ2]
   Google Scholar
• Arriola-Villalobos P, Martinez-de-la-Casa JM, Diaz-Valle D, et al. Glaukos iStent inject® trabecular micro-bypass implantation associated with cataract surgery in patients with coexisting cataract and open-angle glaucoma or ocular hypertension: a long-term study. J Ophthalmol 2016; 2016:1056573
   PubMed Web of Science ®Google Scholar
• Instituto de Evaluación Tecnológica en Salud. Manual para la elaboración de evaluaciones económicas en salud. Bogotá DC: IETS; 2014
   Google Scholar
• Ock M, Han JW, Lee JY, et al. Estimating quality-adjusted life-year loss due to noncommunicable diseases in Korean adults through to the year 2040. Value Health 2015;18:61-6
   PubMed Web of Science ®Google Scholar
• Atkins D, Eccles M, Flottorp S, et al. Systems for grading the quality of evidence and the strength of recommendations I: critical appraisal of existing approaches The GRADE Working Group. BMC Health Serv Res 2004;4:38
   PubMed Web of Science ®Google Scholar
• Mills RP, Budenz DL, Lee PP, et al. Categorizing the stage of glaucoma from pre-diagnosis to end-stage disease. Am J Ophthalmol 2006;141:24-30
   PubMed Web of Science ®Google Scholar
• Tinetti ME, Speechley M, Ginter SF. Risk factors for falls among elderly persons living in the community. N Engl J Med 1988;319:1701-7
   PubMed Web of Science ®Google Scholar
• Stevens JA, Rudd RA. Circumstances and contributing causes of fall deaths among persons aged 65 and older: United States, 2010. J Am Geriatr Soc 2014;62:470-5
   PubMed Web of Science ®Google Scholar
• Yuki K, Asaoka R, Tsubota K. Investigating the influence of visual function and systemic risk factors on falls and injurious falls in glaucoma using the structural equation modelling. PLoS One 2015;10:e0129316
   PubMed Web of Science ®Google Scholar
• Skalska A, Wizner B, Piotrowicz K, et al. The prevalence of falls and their relation to visual and hearing impairments among a nation-wide cohort of older Poles. Exp Gerontol 2013;48:140-6
   PubMed Web of Science ®Google Scholar
• Hong T, Mitchell P, Burlutsky G, et al. Visual impairment and the incidence of falls and fractures among older people: longitudinal findings from the Blue Mountains Eye Study. Invest Ophthalmol Vis Sci 2014;55:7589-93
   PubMed Web of Science ®Google Scholar
• Dirani M, Crowston JG, Taylor PS, et al. Economic impact of primary open-angle glaucoma in Australia. Clin Exp Ophthalmol 2011;39:623-32
   PubMed Web of Science ®Google Scholar
• Lin CH, Liao KC, Pu SJ, et al. Associated factors for falls among the community-dwelling older people assessed y annual geriatric health examinations. PLoS One 2011;6:e18976
   PubMed Web of Science ®Google Scholar
• Lord SR, Dayhew J. Visual risk factors for falls in older people. J Am Geriatr Soc 2001;49:508-15
   PubMed Web of Science ®Google Scholar
• Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487-97
   PubMed Web of Science ®Google Scholar
• van der Valk R, Webers CA, Lumley T, et al. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol 2009;62:1279-83
   PubMed Web of Science ®Google Scholar
• Lin L, Zhao YJ, Chew PT, et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary open-angle glaucoma and ocular hypertension. Ann Pharmacother 2014;48:1585-93
   PubMed Web of Science ®Google Scholar
• Brandt JD, Cantor LB, Katz LJ, et al. Bimatoprost/timolol fixed combination: a 3-month double-masked, randomized parallel comparison to its individual components in patients with glaucoma or ocular hypertension. J Glaucoma 2008;17:211-16
   PubMed Web of Science ®Google Scholar
• Silver LH. Clinical efficacy and safety of brinzolamide (Azopt), a new topical carbonic anhydrase inhibitor for primary open-angle glaucoma and ocular hypertension. Brinzolamide Primary Therapy Study Group. Am J Ophthalmol 1998;126:400-8
   PubMed Web of Science ®Google Scholar
• Centofanti M, Oddone F, Vetrugno M, et al. Efficacy of the fixed combinations of bimatroprost or latanoprost plus timolol in patients uncontrolled with prostaglandin monotherapy: a multicenter, randomized, investigator-masked, clinical study. Eur J Ophthalmol 2009;19:66-71
   PubMed Web of Science ®Google Scholar
• Higginbotham EJ, Olander KW, Kim EE, et al. Fixed combination of latanoprost and timolol vs individual components for primary open-angle glaucoma or ocular hypertension: a randomized, double-masked study. Arch Ophthalmol 2010;128:165-72
   PubMed Web of Science ®Google Scholar
• Hoy SM, Keam SJ, Keating GM. Tavoprosto/timolol. Drugs Aging 2006;23:587-97
   PubMed Web of Science ®Google Scholar
• Schuman JS, Katz GJ, Lewis RA, et al. Efficacy and safety of a fixed combination of travoprost 0.004%/timolol 0.5% ophthalmic solution once daily for open-angle glaucoma or ocular hypertension. Am J Ophthalmol 2005;140:242-50
   PubMed Web of Science ®Google Scholar
• Sacchi M, Specchia C, Williams SE, et al. Efficacy of bimatoprost plus timolol fixed combination in open angle glaucoma patients previously treated with dorzolamide plus timolol fixed combination. Curr Eye Res 2016;41:1433-7
   PubMed Web of Science ®Google Scholar
• Konstas AG, Voudouragkaki IC, Boboridis KG, et al. 24-hour efficacy of travoprost/timolol BAK-free versus latanoprost/timolol fixed combinations in patients insufficiently controlled with latanoprost. Adv Ther 2014;31:592-603
   PubMed Web of Science ®Google Scholar
• Hartleben-Matkin C, Prada D, Mancilla-Vences R. A 4-year retrospective study of add-on therapy to the fixed combination of dorzolamide/timolol for the treatment of POAG. Int J Ophthalmol 2014;7:330-4
   PubMed Web of Science ®Google Scholar
• Lesk MR, Koulis T, Sampalis F, et al. Effectiveness and safety of dorzolamide-timolol alone or combined with latanoprost in open-angle glaucoma or ocular hypertension. Ann Pharmacother 2006; 42:498-504
   Web of Science ®Google Scholar
• The Glaucoma Laser Trial (GLT) and glaucoma laser trial follow-up study: 7. Results. Glaucoma Laser Trial Research Group. Am J Ophthalmol 1995;120:718-31
   PubMed Web of Science ®Google Scholar
• Spiegel D, Wetzel W, Neuhann T, et al. Coexistent primary open-angle glaucoma and cataract: interim analysis of a trabecular micro-bypass stent and concurrent cataract surgery. Eur J Ophthalmol 2009;19:393-9
   PubMed Web of Science ®Google Scholar
• Okeke CO, Quigley HA, Jampel HD, et al. Interventions improve poor adherence with once daily glaucoma medications in electronically monitored patient. Ophthalmology 2009;116:2289-93
   Web of Science ®Google Scholar
• Gupta R, Patil B, Shah BM, et al. Evaluating eye drop instillation technique in glaucoma patients. J Glaucoma 2012;21:189-92
   PubMed Web of Science ®Google Scholar
• Campbell JH, Schwartz G, Labounty B, et al. Comparison of adherence and persistence with bimatoprost 0.01% versus bimatoprost 0.03% topical ophthalmic solutions. Curr Med Res Opin 2013;29:1201-9
   PubMed Web of Science ®Google Scholar
• Barnebey HS, Robin AL. Adherence to fixed-combination versus unfixed travoprost 0.004%/timolol 0.5% for glaucoma or ocular hypertension: a randomized trial. Am J Ophthalmol 2017;176:61-9
   PubMed Web of Science ®Google Scholar
• Lee PP, Walt JG, Doyle JJ, et al. A multicenter, retrospective pilot study of resource use and costs associated with severity of disease in glaucoma. Arch Ophthalmol 2006;124:12-19
   PubMed Web of Science ®Google Scholar
• Weinreb RN, Friedman DS, Fechtner DS, et al. Risk assessment in the management of patients with ocular hypertension. Am J Ophthalmol 2004;138:458-67
   PubMed Web of Science ®Google Scholar
• Lee BS, Kymes SM, Nease RF Jr, et al. The impact of anchor points on utilities for 5 common ophthalmic diseases. Ophthalmology 2008;115:898-903
   PubMed Web of Science ®Google Scholar
• Katsoulis M, Benetou V, Karapetyan T, et al. Excess mortality after hip fracture in elderly persons from Europe and the USA: the CHANCES project. J Intern Med 2017;281:300-10
   PubMed Web of Science ®Google Scholar
• Departamento Administrativo Nacional de Estadística (DANE). Proyecciones nacionales y departamentales de población 2005-2020. Bogotá D.C.: DANE, 2010.
   Google Scholar
• Berdahl JP, Khatana AK, Katz LJ, et al. Cost-comparison of two trabecular micro-bypass stents versus selective laser trabeculoplasty or medication only for intraocular pressure control for patients with open-angle glaucoma. J Med Econ 2017;20:760-6
   PubMed Web of Science ®Google Scholar
• Pizzi LT, Waisbourd M, Hark L, et al. Costs of a community-based glaucoma detection programme: analysis of the Philadelphia Glaucoma Detection and Treatment Project. Br J Ophthalmol 2018;102:225-32
   PubMed Web of Science ®Google Scholar
• Javanbakht M, Azuara-Blanco A, Burr JM, et al. Early lens extraction with intraocular lens implantation for the treatment of primary angle closure glaucoma: an economic evaluation on data from the EAGLE trial. BMJ Open 2017;7:e013254
   PubMed Web of Science ®Google Scholar
• Boodhna T, Crabb DP. More frequent, more costly? Health economic modelling aspects of monitoring glaucoma patients in England. BMC Health Serv Res 2016;16:611
   PubMed Web of Science ®Google Scholar
• Kaplan RI, De Moraes CG, Cioffi GA, et al. Comparative cost-effectiveness of the Baerveldt implant, trabeculectomy with mitomycin, and medical treatment. JAMA Ophthalmol 2015;133:560-7
   PubMed Web of Science ®Google Scholar
• Patel HY, Wagschal LD, Trope GE, et al. Economic analysis of the Ex-PRESS miniature glaucoma device versus trabeculectomy. J Glaucoma 2014;23:385-90
   PubMed Web of Science ®Google Scholar
• Skaat A, Chetrit A, Belkin M, et al. Time trends in the incidence and causes of blindness in Israel. Am J Ophthalmol 2012;153:214-21
   PubMed Web of Science ®Google Scholar